Stock HCM HUTCHMED (CHINA) LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News HUTCHMED (China) Limited Nasdaq

Equities

HCM

US44842L1035

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-28 EDT 		5-day change 1st Jan Change
19.15 USD +2.24% Intraday chart for HUTCHMED (China) Limited -3.77% +5.74%
05-24 HUTCHMED Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology CI
05-20 Hutchmed (China) Chairman Resigns, Successor Named MT

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
HUTCHMED Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology
CI
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be presented at the upcoming EHA2024 Congress
AQ
Hutchmed (China) Chairman Resigns, Successor Named
MT
Hutchmed China Simon To leaves role, succeeded by Dan Eldar
AN
Hutchmed Announces Retirement of Simon To as Chairman, Names Dan Eldar Successor
MT
HUTCHMED Limited Announces Executive Changes
CI
Hutchmed (China) to Present Sovleplenib Phase III Data at EHA2024 Congress
MT
HUTCHMED Limited Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to Be Presented at the Upcoming EHA2024 Congress
CI
Transcript : HUTCHMED Limited Presents at Bank of America Health Care Conference 2024, May-15-2024 02:20 PM
Hutchmed announces trials of HMPL-306 and Surufatinib cancer therapies
AN
Hutchmed Starts Phase 2/3 Trial of Surufatinib Combination Therapy in Pancreatic Cancer
MT
HUTCHMED Limited Initiates the RAPMichael Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
CI
Hutchmed Starts Phase 2/3 Trials for Pancreatic Cancer Drug in China; Shares Rise 3%
MT
Hutchmed Begins Phase 3 Trials for Leukemia Medication in China
MT
HUTCHMED Limited Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naive Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
CI
HUTCHMED Limited Appoints Dr. Renu Bhatia as an Independent Non-Executive Director and a Member of Technical Committee, Effective May 13, 2024
CI
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
AQ
EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug
MT
Hutchmed notes CHMP's positive opinion for fruiquintinib approval
AN
European Medicines Agency Committee Backs Approval of Takeda's Fruquintinib to Treat Colorectal Cancer
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HCM Stock
  4. HCM Stock
  5. News HUTCHMED (China) Limited